Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Short-term Investments (2019 - 2026)

DiaMedica Therapeutics filings provide 8 years of Short-term Investments readings, the most recent being $46.5 million for Q1 2026.

  • Quarterly Short-term Investments rose 37.75% to $46.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $46.5 million through Mar 2026, up 37.75% year-over-year, with the annual reading at $44.2 million for FY2025, 7.59% up from the prior year.
  • Short-term Investments hit $46.5 million in Q1 2026 for DiaMedica Therapeutics, up from $44.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $52.0 million in Q3 2025 and bottomed at $9000.0 in Q3 2022.
  • Average Short-term Investments over 5 years is $35.0 million, with a median of $40.0 million recorded in 2024.
  • The largest annual shift saw Short-term Investments crashed 99.97% in 2022 before it surged 491377.78% in 2023.
  • DiaMedica Therapeutics' Short-term Investments stood at $28.8 million in 2022, then skyrocketed by 68.04% to $48.4 million in 2023, then fell by 14.95% to $41.1 million in 2024, then rose by 7.59% to $44.2 million in 2025, then rose by 5.02% to $46.5 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Short-term Investments are $46.5 million (Q1 2026), $44.2 million (Q4 2025), and $52.0 million (Q3 2025).